Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-04-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report explicitly states it is unaudited and covers the period January to March 2023, which is a period shorter than a full fiscal year. The presence of comprehensive financial statements and analysis for a quarter indicates this is an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification, and the document length and content confirm it is the full report itself, not just a publication announcement or regulatory filing. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2023
2023-04-27 Chinese
第一届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the first Supervisory Board of the company, including approvals of various reports such as the 2022 Supervisory Board Work Report, 2022 Financial Final Report, 2023 Financial Budget Report, 2022 Profit Distribution Plan, and others. It also mentions that these reports and proposals will be submitted to the 2022 Annual General Meeting for approval. The document is not the reports themselves but a formal announcement of the Supervisory Board's decisions and approvals. It includes no actual financial statements or detailed financial data but references other reports published elsewhere. The document length is 4241 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board meeting resolutions and approvals, not the full annual report or financial report itself.
2023-04-27 Chinese
关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of the company 海创药业股份有限公司. It includes details such as the date and location of the meeting, voting procedures, agenda items to be discussed and voted on, and instructions for shareholders to attend or vote by proxy. It does not contain the actual annual report or financial statements but rather the announcement and logistical information for the AGM. The document length is 3881 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-04-27 Chinese
关于续聘公司2023年度财务及内部控制审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's financial and internal control audit firm for the year 2023. It details the auditing firm information, the audit committee's review, independent directors' opinions, and board and supervisory committee approvals. It does not contain actual financial statements or audit results but rather the procedural and approval information related to the audit firm appointment. The document length is 3363 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR). FY 2023
2023-04-27 Chinese
中信证券股份有限公司关于海创药业股份有限公司2022年度募集资金存放与实际使用情况的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2022 annual special audit opinion on the deposit and actual use of raised funds by Haichuang Pharmaceutical Co., Ltd. It includes specifics on the amount raised, usage, management, and compliance with regulatory requirements. The document references regulatory guidelines related to fundraising management and includes audit opinions from Deloitte Huayong CPA firm. The content focuses on the management and use of capital raised through an IPO and the compliance with relevant securities regulations. This aligns with a Capital/Financing Update (CAP) filing, as it provides a comprehensive update on fundraising activities, fund usage, and regulatory compliance related to capital raised. The document is not an annual report, audit report, or earnings release, but a specialized report on fundraising and capital use, fitting the CAP category.
2023-04-27 Chinese
独立董事关于对外担保情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special statement by independent directors regarding the company's external guarantees for the fiscal year 2022. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content is a formal attestation that no external guarantees were made, and it includes signatures of independent directors. The document is short (572 characters) and serves as a regulatory compliance statement rather than a full financial report or audit. It does not contain financial data or detailed analysis but is a formal regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which covers compliance documents and attestations that do not fit other categories.
2023-04-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.